Biochemical criteria of toxicity of therapy with high doses of methotrexate in children with osteosarcoma
Methotrexate (Mtx) is a cytotoxic drug from the group of antimetabolites, folic acid antagonists. High-dose (HD) Mtx in pediatric oncology are used for the treatment of osteosarcoma (OS), and other types of tumors. This therapy has allowed to achieve a five-year relapse-free survival rates up to 80...
Saved in:
Main Authors: | A. M. Strizhevskaya, E. G. Golovnya, A. Z. Dzampaev, V. N. Baykova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-06-01
|
Series: | Успехи молекулярной онкологии |
Subjects: | |
Online Access: | https://umo.abvpress.ru/jour/article/view/8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic drug monitoring of methotrexate after its administration in high doses for osteosarcoma treatment in children
by: A. M. Strizhevskaya, et al.
Published: (2020-04-01) -
Genetic polymorphisms as predictors of methotrexate toxicity: literature review
by: G. A. Radzhabova, et al.
Published: (2024-04-01) -
Administration of high dose methotrexate monitoring a single serum methotrexate level at 72 hours
by: Saksham Singh, et al.
Published: (2025-06-01) -
Therapeutic drug monitoring of methotrexate and its metabolites in the red blood cells and mononuclear cells of patients with rheumatoid arthritis
by: G. I. Gridneva, et al.
Published: (2020-11-01) -
Early toxicity of high-dose methotrexate in the treatment of non-hodgkin lymphomas in children
by: Z. K. Simavonyan, et al.
Published: (2025-03-01)